2-Hydroxy-1,2-bis(4-methoxyphenyl)ethanone | CAS:119-52-8

We serve 2-Hydroxy-1,2-bis(4-methoxyphenyl)ethanone CAS:119-52-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
2-Hydroxy-1,2-bis(4-methoxyphenyl)ethanone

Synonyms:
2-Hydroxy-1,2-bis(4-methoxyphenyl)ethanone
4,4'-Dimethoxybenzoin
Ethanone, 2-hydroxy-1,2-bis(4-methoxyphenyl)-
2-Hydroxy-4'-methoxy-2-(4-methoxyphenyl)acetophenone
2-Hydroxy-1,2-bis(4-methoxyphenyl)ethanone
 
Molecular Formula: C16H16O4
Molecular Weight:  272.29600

Appearance and properties: yellow powder
Density: 1.194 g/cm3
Boiling point: 459.4ºC at 760 mmHg
Melting point: 108-111 °C(lit.)
Flash point: 171ºC
Refractive index: 1.578

Items Requirements Testing resultS
Appearance White powder White powder
Melting Point 108-111 °C 108℃
Assay(HPLC) >98% 98.62%
Loss on drying ≤1.0% 0.58%
href="javascript:void(0);" Conclusion The product is up to standard.
 



Contact us for information like 2-Hydroxy-1,2-bis(4-methoxyphenyl)ethanone chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-Hydroxy-1,2-bis(4-methoxyphenyl)ethanone physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4,4′-Dimethoxybenzoin Use and application,Ethanone, 2-hydroxy-1,2-bis(4-methoxyphenyl)- technical grade,usp/ep/jp grade.


Related News: There’s a few factors that play into this.Acetic acid 4-acetoxy-7-(3-acetoxy-propyl)-5,8-dihydro-naphthalen-1-yl ester manufacturer There’s a few factors that play into this.3-(2-cyclopentyl-1-oxoisoindolin-4-yl)-5-nitroquinoxalin-2(1H)-one supplier Advanced clinical trials with the Company’s lead compound, rigosertib, are aimed at what the Company believes are unmet medical needs of patients with MDS.((3aS,4aR,7aR,8aR)-2,2,6,6-tetramethyl-8-oxotetrahydrobenzo[1,2-d:4,5-d’]bis([1,3]dioxole)-3a(4H)-yl)methyl 4-methylbenzenesulfonate vendor Advanced clinical trials with the Company’s lead compound, rigosertib, are aimed at what the Company believes are unmet medical needs of patients with MDS.The StartScore model was developed by the company’s in-house supply chain experts based on actual performance data.